Management

Prof. Liqun Zhang, PhD

Chief Executive Officer

Prof. Liqun Zhang holds a Ph.D. in medical Genetics from the University of Toronto, Canada and is also a guest Professor of Shandong University of Traditional Chinese Mmedicine (TCM).

Besides her extensive experience as a practitioner of Chinese medicine, she is also teaching Chinese herbal medicine at the Medical University of Vienna and is a book author on TCM.

She has also gained extensive experience in an Austrian biotech company.

 

 

 

Chief Scientific Officer

 

Dr. Matheus Dyczynski studied Molecular Biology in Maastricht (Netherlands) and did his Master's degree in Infection Biology in Uppsala (Sweden). Here, he graduated as member of the Uppsala Graduate School for Biomedical Research with his thesis “Semliki-Forest-Virus as oncolytic agent in the treatment of neuroblastoma”. He received his PhD in Molecular Medicine from Karolinska Institute in Stockholm (Sweden) studying the effects of autophagy in anticancer chemotherapy. Leaving academy, he worked at Sprint Biosciences (Sweden) with a focus on drug development and target validation. In 2019 he joined ACUS Laboratories in Cologne as a scientist working closely with Dr. Moritz Horn on forward genetic screening systems. In 2021 he joined JLP Health in Vienna (Austria) where he was head of the drug target screening group in addition to playing an integral role in the JLP Health’s contribution to the European project innovative medicines initiative “MAD-CoV2”. In 2023 he joined Angal Biotechnologies Co Ltd as Chief Scientific Officer.

 

Email: matheus.dyczynski@angalbio.com